Last reviewed · How we verify

Jenzyl — Competitive Intelligence Brief

Jenzyl (RIDAFOROLIMUS) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ridaforolimus. Area: Other.

discontinued ridaforolimus Dual specificity tyrosine-phosphorylation-regulated kinase 1B, Serine/threonine-protein kinase mTOR Other Small molecule Live · refreshed every 30 min

Target snapshot

Jenzyl (RIDAFOROLIMUS). Jenzyl blocks the mTOR pathway, which is a key regulator of cell growth and division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Jenzyl TARGET RIDAFOROLIMUS discontinued ridaforolimus Dual specificity tyrosine-phosphorylation-regulated kinase 1B, Serine/threonine-protein kinase mTOR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ridaforolimus class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jenzyl — Competitive Intelligence Brief. https://druglandscape.com/ci/ridaforolimus. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: